Pages

Pages

Thursday, 12 December 2013

Sprout Pharmaceuticals Appeals FDA Decision on NDA for Flibanserin to Treat Hypoactive Sexual Desire Disorder in Premenopausal Women « New Drug Approvals

No comments:

Post a Comment